Sarah Milner
Sarah is a Director of Medical Writing at ELIQUENT Life Sciences Ltd, with specialisms including paediatrics and rare disease. She is also a member of the editorial team for the EMWA journal and a member of the Regulatory Rapporteur Editorial Board.
Industry newsFDA launches framework for accelerating development of individualised therapies for ultra-rare diseases
This industry news explores new FDA draft guidance that considers the use of the plausible mechanism framework to develop individualised medicines where randomised controlled trials are not feasible.